Preoperative Androgen Deprivation Therapy: Artificial Lowering of Serum Prostate Specific Antigen without Downstaging the Tumor (Q72073904)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7681117%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

title

Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7681117%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

Preoperative Androgen Deprivation Therapy: Artificial Lowering of Serum Prostate Specific Antigen without Downstaging the Tumor (English)

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

13 August 2024

J E Oesterling

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7681117%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

P. E. Andrews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7681117

13 August 2024

V. J. Suman

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7681117

13 August 2024

H. Zincke

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7681117

13 August 2024

R. P. Myers

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7681117

13 August 2024

language of work or name

English

0 references

publication date

1 April 1993

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7681117%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

23 October 2019

https://api.elsevier.com/content/article/PII:S0022534717362067?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

https://api.elsevier.com/content/article/PII:S0022534717362067?httpAccept=text/plain

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

http://www.jurology.com/doi/pdf/10.1016/S0022-5347%2817%2936206-7

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

13 August 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7681117%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

volume

149

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7681117%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7681117%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

page(s)

779-782

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7681117%20AND%20SRC:MED&resulttype=core&format=json

Relative reliability of five serially measured markers for prognosis of progression in prostate cancer

23 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy.

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation)

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retrospective study based upon 25 years of experience

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

The TNM classification of prostate cancer

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Pathologic Differentiation and Prognosis of Prostatic Carcinoma

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Radical retropubic prostatectomy and pelvic lymphadenectomy for high-stage cancer of the prostate

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Individual Comparisons by Ranking Methods

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Note on the sampling error of the difference between correlated proportions or percentages

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

13 August 2024

1 reference

https://api.crossref.org/works/10.1016/S0022-5347(17)36206-7

13 August 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7681117%20AND%20SRC:MED&resulttype=core&format=json

23 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7681117%20AND%20SRC:MED&resulttype=core&format=json